The Priority Review

Clinical trials Brief

Orphalan expands TRADITiONAL study into China, first participant randomised worldwide

Orphalan SA announced the expansion of its Phase 3 TRADITiONAL Study into China, marking the first participant worldwide randomised at The Second Affiliated Hospital of Zhejiang University School of Medicine. The study evaluates once-daily trientine tetrahydrochloride versus D-penicillamine over 48 weeks.

Primary source

Company press release (PR Newswire), November 12, 2026

Orphalan Expands Global Phase 3 TRADITiONAL Study in Wilson Disease to China Marking First Patient Randomised Worldwide

Read the source: Orphalan Expands Global Phase 3 TRADITiONAL Study in Wilson Disease to China Marking First Patient Randomised Worldwide prnewswire.com

Machine-summarized from the source above; not independently reported. How we use automation